

# 甲磺酸伊马替尼药物报告

## imatinib mesylate Drug Report

[打印报告](#)

### 摘要信息

药物英文名	imatinib mesylate
药物中文名	甲磺酸伊马替尼
药物别名	imatinib mesilate,Gleevec; STI-571
原研单位	NOVARTIS PHARMACEUTICALS CORP
全球最高状态	2001年批准上市
中国是否上市	是

### 药物概述

甲磺酸伊马替尼(Imatinib mesylate)由诺华 (Novartis) 研发, 首先于2001年5月10日获美国食品药品监督管理局 (FDA) 批准上市, 之后于2001年11月7日获欧洲药物管理局 (EMA) 批准上市, 于2005年3月9日获日本医药品医疗器械综合机构 (PMDA) 批准上市。由诺华在美国上市销售(商品名:Gleevec)。甲磺酸伊马替尼是一种 Bcr-Abl酪氨酸激酶抑制剂, 能够抑制Bcr-Abl阳性细胞系及费城染色体阳性慢性粒细胞白血病的新鲜细胞的增殖和诱导其凋亡。伊马替尼也是血小板衍生生长因子 (PDGF)、干细胞因子 (SCF), c-Kit酪氨酸激酶抑制剂, 从而抑制由PDGF和SCF介导的细胞活动。在体外, 伊马替尼抑制活化的c-Kit突变表达的胃肠道间质瘤 (GIST) 细胞的增殖并诱导其死亡。该药用于治疗慢性粒细胞白血病 (CML), 胃肠道间质瘤 (GIST) 以及其他恶性肿瘤。Gleevec为口服薄膜衣片, 每片含有100 mg或400 mg伊马替尼。推荐剂量为对于慢性期CML成年患者, 每次400 mg, 每日1次; 对于急变期或加速期CML成年患者, 每次600 mg, 每日1次。

### API信息


#### 结构式

化学名称: Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate salt

CAS登记号: 220127-57-1

分子式: C<sub>29</sub>H<sub>31</sub>N<sub>7</sub>O·CH<sub>3</sub>SO<sub>3</sub>H

分子量: 589.71



## 药理作用

### ATC分类

L01XE01 抗肿瘤药和免疫机能调节药 > 抗肿瘤药 > 其它抗肿瘤药物 > 蛋白激酶抑制剂

### 作用靶点

Kit tyrosine kinase inhibitor

## 美国上市情况(5条)

申请号	商标名	活性成分	剂型	批准时间	申请机构
021335	GLEEVEC	IMATINIB MESYLATE	CAPSULE;ORAL	2001-05-10	
021588	GLEEVEC	IMATINIB MESYLATE	TABLET;ORAL	2003-04-18	
078340	IMATINIB MESYLATE	IMATINIB MESYLATE	TABLET;ORAL	2015-12-03	
204285	IMATINIB MESYLATE	IMATINIB MESYLATE	TABLET;ORAL	2016-08-04	
079179	IMATINIB MESYLATE	IMATINIB MESYLATE	TABLET;ORAL	2016-08-05	

## 日本上市情况(22条)

序号	商标名	活性成份	申请类型	申请公司	批准日期
1	Glivec Tablets 100 mg	Imatinib mesilate	Change	Novartis Pharma K.K.	2012/02 /22
2	Glivec Tablets 100mg	Imatinib mesilate	change	Novartis Pharma K.K..	2007/01 /31

3	イマチニブ錠100mg「サワイ」/ イマチニブ錠200mg「サワイ」	イマチニブ メシル酸塩	沢井製薬株式会社
4	イマチニブ錠100mg「NK」	イマチニブ メシル酸塩	日本化薬株式会社
5	イマチニブ錠100mg「オーハラ」	イマチニブ メシル酸塩	大原薬品工業株式会社
6	イマチニブ錠100mg「明治」/ イマチニブ錠200mg「明治」	イマチニブ メシル酸塩	Meiji Seika ファルマ株 式会社
7	イマチニブ錠100mg「ヤクルト」	イマチニブ メシル酸塩	株式会社ヤクルト本社; 高田製薬株式会社
8	イマチニブ錠100mg「DSEP」	イマチニブ メシル酸塩	第一三共エスファ株式 会社; 第一三共株式会 社
9	イマチニブ錠100mg「KN」	イマチニブ メシル酸塩	小林化工株式会社
10	イマチニブ錠100mg「TCK」	イマチニブ メシル酸塩	辰巳化学株式会社
11	イマチニブ錠200mg「ヤクルト」	イマチニブ メシル酸塩	株式会社ヤクルト本社; 高田製薬株式会社
12	イマチニブ錠100mg「ケミファ」	イマチニブ メシル酸塩	日本ケミファ株式会社
13	イマチニブ錠100mg「テバ」	イマチニブ メシル酸塩	武田薬品工業株式会社; 武田テバファーマ株式 会社
14	イマチニブ錠100mg「ファイザ ー」	イマチニブ メシル酸塩	マイラン製薬株式会社; ファイザー株式会社
15	イマチニブ錠100mg「EE」	イマチニブ メシル酸塩	エルメッド エーザイ株 式会社; エーザイ株式 会 社
16	イマチニブ錠100mg「JG」	イマチニブ メシル酸塩	日本ジェネリック株式 会社
17	イマチニブ錠100mg「NSKK」	イマチニブ メシル酸塩	日本新薬株式会社; 共創 未来ファーマ株式会社
18	イマチニブ錠100mg「トーワ」/ イマチニブ錠200mg「トーワ」	イマチニブ メシル酸塩	東和薬品株式会社
19	イマチニブ錠100mg「日医工」/ イマチニブ錠200mg「日医工」	イマチニブ メシル酸塩	日医工株式会社
20	イマチニブ錠100mg「ニプロ」/ イマチニブ錠200mg「ニプロ」	イマチニブ メシル酸塩	ニプロ株式会社
21	イマチニブ錠100mg「ニプロ」	イマチニブ メシル酸塩	共和クリティケア株式 会社; ニプロ株式会社
22	グリベック錠100mg	イマチニブ メシル酸塩	ノバルティス ファーマ 株式会社

## 中国上市情况(10条)

药品名称	批准文号	药品规格	生产厂商	国产厂家数量	是否医保
甲磺酸伊马替尼	国药准字 H20130074	----	连云港润众制药有限公司	3	
甲磺酸伊马替尼胶囊	国药准字 H20133198	100mg(按 C29H31N7O计算)	正大天晴药业集团股份有 限公司	1	
甲磺酸伊马替尼片	国药准字 H20133200	0.1g(以 C29H31N7O计)	江苏豪森药业集团有限公 司	2	
甲磺酸伊马替尼	国药准字 H20130075	----	江苏豪森药业集团有限公 司	3	
甲磺酸伊马替尼胶囊	国药准字 H20133199	50mg(按 C29H31N7O计算)	正大天晴药业集团股份有 限公司	1	
甲磺酸伊马替尼片	国药准字 H20143340	0.1g(按 C29H31N7O计)	石药集团欧意药业有限公 司	2	
甲磺酸伊马替尼	国药准字 H20140115	----	石药集团欧意药业有限公 司	3	
甲磺酸伊马替尼片	H20150112	0.1g(按伊马替尼 计)	Novartis Pharma Produktions GmbH	德国进口	
甲磺酸伊马替尼片	H20150298	0.4g(按伊马替尼 计)	Novartis Pharma Stein AG	瑞士进口	
甲磺酸伊马替尼胶囊	H20150294	0.1g (按伊马替尼 计)	Novartis Pharma Stein AG	瑞士进口	

## 中国注册申报情况(149条)

隐藏

受理号码	药品名称	申请类型	注册分类	承办日期	企业名称	办理状态	状态开始日期	审批结论
CXL008 88	STI571 胶囊	新药	1	2001- 01-05	香港诺华 制药有限 公司北京 代表处	在审批		
CXL008 87	STI571 胶囊	新药	1	2001- 01-05				批准
A20010 097	甲磺酸伊 马替尼	新药		2001- 11-22	香港诺华 制药有限 公司北京 代表处	审批完毕		批准
B20020 128	甲磺酸伊 马替尼胶 囊	进口		2002- 10-24	香港诺华 制药有限 公司北京 代表处	审批完毕	2003-03-19	批准

J030034 2	甲磺酸伊 马替尼胶 囊	补充申请		2003- 04-08	香港诺华 制药有限 公司北京 代表处	审批完毕	2003-10-23	批准临床
J040133 3	甲磺酸伊 马替尼胶 囊	进口再注 册		2004- 07-21	北京诺华 制药有限 公司	制证完毕 - 已发批 件	2005-01-06	批准再注 册
J040000 2	甲磺酸伊 马替尼片	进口	3.1	2004- 08-09	香港诺华 制药有限 公司北京 代表处	制证完毕 - 已发批 件	2005-01-17	批准进口
J040000 1	甲磺酸伊 马替尼片	进口	3.1	2004- 08-09	香港诺华 制药有限 公司北京 代表处	制证完毕 - 已发批 件	2005-01-17	批准进口
J040230 0	甲磺酸伊 马替尼胶 囊	补充申请		2004- 12-22		已发批件	2005-05-19	批准临床
JYHB05 00346	甲磺酸伊 马替尼片	补充申请		2005- 05-25	北京诺华 制药有限 公司	已发批件	2005-09-28	批准临床
JYHB05 00347	甲磺酸伊 马替尼片	补充申请		2005- 05-25	北京诺华 制药有限 公司	已发件	2005-09-28	批准临床
JYHB05 00780	甲磺酸伊 马替尼胶 囊	补充申请		2005- 11-25	北京诺华 制药有限 公司	制证结束 待发送- 未批准	2006-04-18	批准补充
JYHB05 00807	甲磺酸伊 马替尼片	补充申请		2005- 12-07	北京诺华 制药有限 公司	制证完毕 - 待发批 件	2006-06-19	批准补充
JYHB05 00808	甲磺酸伊 马替尼片	补充申请		2005- 12-07	北京诺华 制药有限 公司	制证结束 待发送- 已批准	2006-06-19	批准补充
JYHB06 00461	甲磺酸伊 马替尼片	补充申请		2006- 09-06	北京诺华 制药有限 公司	已发批件	2007-11-19	批准补充
JYHB06 00462	甲磺酸伊 马替尼片	补充申请		2006- 09-06	北京诺华 制药有限 公司	已发批件	2007-11-19	批准补充
JXHL07 00206	甲磺酸伊 马替尼片	进口	3.4	2007- 07-25	北京诺华 制药有限 公司	制证完毕 - 已发批 件	2009-02-11	批准进口
JXHL07 00207	甲磺酸伊 马替尼片	进口	3.4	2007- 07-25	北京诺华 制药有限 公司	制证完毕 - 已发批 件	2009-02-11	批准进口
JYHB07	甲磺酸伊			2007-	北京诺华	制证完毕		

00993	马替尼片	补充申请		09-25	制药有限公司	- 已发批件	2008-04-11	不批准
JYHB0700992	甲磺酸伊马替尼片	补充申请		2007-09-25	北京诺华制药有限公司	制证完毕 - 已发批件	2008-04-11	不批准
JYHB0701003	甲磺酸伊马替尼胶囊	补充申请		2007-09-25	北京诺华制药有限公司	制证完毕 - 已发批件	2008-04-11	不批准
JYHB0701149	甲磺酸伊马替尼片	补充申请		2007-11-28	北京诺华制药有限公司	制证完毕 - 已发批件	2008-05-23	批准补充
JYHB0701150	甲磺酸伊马替尼片	补充申请		2007-11-28	北京诺华制药有限公司	制证完毕 - 已发批件	2008-05-23	批准补充
JXHL0800401	甲磺酸伊马替尼片	进口		2008-12-02	Novartis Pharma Schweiz AG	制证完毕 - 已发批件	2010-04-09	批准进口
JXHL0800402	甲磺酸伊马替尼片	进口		2008-12-02	Novartis Pharma Schweiz AG	制证完毕 - 已发批件	2010-04-09	批准进口
JXHL0900090	甲磺酸伊马替尼片	进口		2009-03-26	Novartis Pharma Schweiz AG	制证完毕 - 已发批件	2010-05-24	批准进口
JXHL0900089	甲磺酸伊马替尼片	进口		2009-03-26	Novartis Pharma Schweiz AG	制证完毕 - 已发批件	2010-05-24	批准进口
JYHZ0900238	甲磺酸伊马替尼胶囊	进口再注册		2009-07-09	Novartis Pharma Schweiz AG	制证完毕 - 已发批件	2010-04-22	批准再注册
JYHZ0900262	甲磺酸伊马替尼片	进口再注册		2009-07-16	Novartis Pharma Schweiz AG	制证完毕 - 已发批件	2010-04-27	批准再注册
JYHZ0900261	甲磺酸伊马替尼片	进口再注册		2009-07-21	Novartis Pharma Schweiz AG	制证完毕 - 已发批件	2010-04-27	批准再注册

JYHB10 00793	甲磺酸伊 马替尼胶 囊	补充申请		2010- 09-14	北京诺华 制药有限 公司	制证完毕 - 已发批 件	2011-02-14	批准补充
CXHS10 00211	甲磺酸伊 马替尼	新药	3.1	2010- 10-27	江苏正大 天晴药业 股份有限 公司	制证完毕 - 已发批 件	2011-12-27	批准临床
CYHS10 00855	甲磺酸伊 马替尼胶 囊	仿制	6	2011- 02-22	江苏正大 天晴药业 股份有限 公司	制证完毕 - 已发批 件	2011-12-22	批准临床
CYHS10 00854	甲磺酸伊 马替尼胶 囊	仿制	6	2011- 02-22	江苏正大 天晴药业 股份有限 公司	制证完毕 - 已发批 件	2011-12-22	批准临床
CXHS11 00035	甲磺酸伊 马替尼	新药	3.1	2011- 04-26	江苏豪森 医药集团 连云港宏 创医药有 限公司	制证完毕 - 已发批 件	2011-11-15	终止审批 程序
CYHS11 00172	甲磺酸伊 马替尼片	仿制	6	2011- 05-16	江苏豪森 药业股份 有限公司	制证完毕 - 已发批 件	2011-11-15	终止审批 程序
CYHS11 01059	甲磺酸伊 马替尼片	仿制	6	2011- 09-20	江苏豪森 药业股份 有限公司	制证完毕 - 已发批 件	2012-09-05	批准临床
CXHS11 00191	甲磺酸伊 马替尼	新药	3.1	2011- 09-20	江苏豪森 医药集团 连云港宏 创医药有 限公司	制证完毕 - 已发批 件	2012-08-28	批准临床
JYHB11 00867	甲磺酸伊 马替尼片	补充申请		2011- 10-18	Novarti s Pharma Schweiz AG	制证完毕 - 已发批 件	2014-01-30	批准补充
JYHB11 00866	甲磺酸伊 马替尼胶 囊	补充申请		2011- 10-18	北京诺华 制药有限 公司	制证完毕 - 已发批 件	2014-01-22	
JYHB11 00868	甲磺酸伊 马替尼片	补充申请		2011- 10-18	Novarti s Pharma Schweiz AG	制证完毕 - 已发批 件	2014-01-30	批准补充
CXHS11 00181	甲磺酸伊 马替尼	新药	3.1	2011- 11-14	重庆福安 药业(集 团)股份 有限公司	制证完毕 - 已发批 件	2013-04-17	批准临床

CYHS1101033	甲磺酸伊马替尼胶囊	仿制	6	2011-11-23	重庆市庆余堂制药有限公司	制证完毕 - 已发批件	2013-04-23	批准临床
CYHS1101034	甲磺酸伊马替尼片	仿制	6	2011-11-23	重庆市庆余堂制药有限公司	制证完毕 - 已发批件	2013-04-23	批准临床
CYHS1100884	甲磺酸伊马替尼片	仿制	6	2011-12-05	石药集团中奇制药技术(石家庄)有限公司	制证完毕 - 已发批件	2013-04-25	批准临床
CXHS1100158	甲磺酸伊马替尼	新药	3.1	2011-12-05	石药集团中奇制药技术(石家庄)有限公司	制证完毕 - 已发批件	2013-04-17	批准临床
JYHB1200234	甲磺酸伊马替尼胶囊	补充申请		2012-03-16	北京诺华制药有限公司	制证完毕 - 已发批件	2013-01-15	批准补充
JYHB1200235	甲磺酸伊马替尼片	补充申请		2012-03-16	Novartis Pharma Schweiz AG	制证完毕 - 已发批件	2013-01-17	批准补充
JYHB1200236	甲磺酸伊马替尼片	补充申请		2012-03-16	Novartis Pharma Schweiz AG	制证完毕 - 已发批件	2013-01-17	批准补充
CXHS1200063	甲磺酸伊马替尼	新药	3.1	2012-04-20	南京先声东元制药有限公司	制证完毕 - 已发批件	2013-07-09	批准临床
CXHS1200083	甲磺酸伊马替尼	新药	3.1	2012-05-14	齐鲁天和惠世制药有限公司	制证完毕 - 已发批件	2013-07-09	批准临床
CYHS1200412	甲磺酸伊马替尼片	仿制	6	2012-05-21	齐鲁制药(海南)有限公司	制证完毕 - 已发批件	2013-07-09	批准临床
CYHS1200413	甲磺酸伊马替尼片	仿制	6	2012-05-21	齐鲁制药(海南)有限公司	制证完毕 - 已发批件	2013-07-09	批准临床
JXHL1200168	甲磺酸伊马替尼片	进口		2012-05-22	Pliva Croatia Ltd.	制证完毕 - 已发批件	2014-12-01	批准临床
JXHL1200167	甲磺酸伊马替尼片	进口		2012-06-13	Pliva Croatia Ltd.	制证完毕 - 已发批件	2014-12-01	批准临床



CXHS12 00122	甲磺酸伊 马替尼	新药	3.1	2012- 06-19	连云港润 众制药有 限公司	制证完毕 - 已发批 件	2013-07-03	批准生产
CYHS12 90061	甲磺酸伊 马替尼胶 囊	仿制	6	2012- 06-19	江苏正大 天晴药业 股份有限 公司	制证完毕 - 已发批 件	2013-07-03	批准生产
CYHS12 90062	甲磺酸伊 马替尼胶 囊	仿制	6	2012- 06-19	江苏正大 天晴药业 股份有限 公司	制证完毕 - 已发批 件	2013-07-03	批准生产
CXHS12 00087	甲磺酸伊 马替尼	新药	3.1	2012- 07-06	浙江九洲 药业股份 有限公司	制证完毕 - 已发批 件	2014-09-09	批准临床
CYHS12 00255	甲磺酸伊 马替尼片	仿制	6	2012- 07-13	南京先声 东元制药 有限公司	制证完毕 - 已发批 件	2013-07-12	批准临床
CYHS12 00838	甲磺酸伊 马替尼胶 囊	仿制	6	2012- 11-08	江苏万高 药业有限 公司	制证完毕 - 已发批 件	2014-09-03	批准临床
CYHS12 90119	甲磺酸伊 马替尼片	仿制	6	2012- 12-20	江苏豪森 药业股份 有限公司	制证完毕 - 已发批 件	2013-07-03	批准生产
CXHS12 00336	甲磺酸伊 马替尼	新药	3.1	2012- 12-21	江苏豪森 医药集团 连云港宏 创医药有 限公司	制证完毕 - 已发批 件	2013-07-03	批准生产
JXHL13 00002	甲磺酸伊 马替尼	进口		2013- 01-14	北京法马 苏提克咨 询有限公 司	制证完毕 - 已发批 件	2015-12-17	不批准
CXHS12 00263	甲磺酸伊 马替尼	新药	3.1	2013- 01-28	珠海联邦 制药股份 有限公司	制证完毕 - 已发批 件	2015-10-28	批准临床
CYHS12 01285	甲磺酸伊 马替尼胶 囊	仿制	6	2013- 02-04	珠海联邦 制药股份 有限公司 中山分公 司	制证完毕 - 已发批 件	2016-01-22	批准临床
CYHS12 01598	甲磺酸伊 马替尼片	仿制	6	2013- 02-04	杭州中美 华东制药 有限公司	制证完毕 - 已发批 件	2015-12-24	批准临床
CXHS12 00275	甲磺酸伊 马替尼	新药	3.1	2013- 02-06	湖北葛店 人福药业 有限责任 公司	制证完毕 - 已发批 件	2013-06-18	

CXHS12 00332	甲磺酸伊 马替尼	新药	3.1	2013- 02-20	山东新时 代药业有 限公司	制证完毕 - 已发批 件	2015-12-24	批准临床
CXHS12 00365	甲磺酸伊 马替尼	新药	3.1	2013- 03-07	浙江海正 药业股份 有限公司	制证完毕 - 已发批 件	2015-12-24	批准临床
CXHS12 00375	甲磺酸伊 马替尼	新药	3.1	2013- 04-07	山东方明 药业集团 股份有限 公司	制证完毕 - 已发批 件	2016-01-14	批准临床
CXHS12 00313	甲磺酸伊 马替尼	新药	3.1	2013- 04-28	上海创诺 制药有限 公司	制证完毕 - 已发批 件	2015-12-30	批准临床
CYHS12 01806	甲磺酸伊 马替尼胶 囊	仿制	6	2013- 05-08	浙江海正 药业股份 有限公司	制证完毕 - 已发批 件	2015-12-24	批准临床
CYHS12 01537	甲磺酸伊 马替尼片	仿制	6	2013- 05-09	上海创诺 制药有限 公司	制证完毕 - 已发批 件	2015-12-30	批准临床
JYHB13 00601	甲磺酸伊 马替尼片	补充申请		2013- 05-20	Novarti s Pharma Schweiz AG	制证完毕 - 已发批 件	2014-01-22	
JYHB13 00602	甲磺酸伊 马替尼胶 囊	补充申请		2013- 05-20	北京诺华 制药有限 公司	制证完毕 - 已发批 件	2014-01-22	
JYHB13 00600	甲磺酸伊 马替尼片	补充申请		2013- 05-20	Novarti s Pharma Schweiz AG	制证完毕 - 已发批 件	2014-01-22	
CYHS12 01658	甲磺酸伊 马替尼片	仿制	6	2013- 05-28	山东新时 代药业有 限公司	制证完毕 - 已发批 件	2015-12-30	批准临床
CXHS13 00050	甲磺酸伊 马替尼	新药	3.1	2013- 06-18	山东金城 钟化生物 药业有限 公司	制证完毕 - 已发批 件	2016-01-21	批准临床
CYHS13 00265	甲磺酸伊 马替尼片	仿制	6	2013- 07-01	重庆圣华 曦药业股 份有限公 司	制证完毕 - 已发批 件	2015-12-30	批准临床
CXHS13 00051	甲磺酸伊 马替尼	新药	3.1	2013- 07-01	重庆圣华 曦药业股 份有限公 司	制证完毕 - 已发批 件	2015-12-30	批准临床

CYHS13 00266	甲磺酸伊 马替尼片	仿制	6	2013- 07-15	重庆圣华 曦药业股 份有限公 司	制证完毕 - 已发批 件	2016-01-14	批准临床
CYHS12 01831	甲磺酸伊 马替尼片	仿制	6	2013- 08-07	山东方明 药业集团 股份有限 公司	制证完毕 - 已发批 件	2016-01-14	批准临床
CYHS13 90048	甲磺酸伊 马替尼片	仿制	6	2013- 08-13	石药集团 中奇制药 技术(石 家庄)有 限公司	制证完毕 - 已发批 件	2014-10-31	批准生产
CXHS13 00113	甲磺酸伊 马替尼	新药	3.1	2013- 08-16	南京优科 制药有限 公司	制证完毕 - 已发批 件	2016-01-21	批准临床
CYHS13 00340	甲磺酸伊 马替尼片	仿制	6	2013- 08-20	海南锦瑞 制药有限 公司	制证完毕 - 已发批 件	2016-01-14	批准临床
CXHS13 00181	甲磺酸伊 马替尼	新药	3.1	2013- 08-20	石药集团 中奇制药 技术(石 家庄)有 限公司	制证完毕 - 已发批 件	2014-11-06	批准生产
CXHS13 00175	甲磺酸伊 马替尼	新药	3.1	2013- 09-06	北大国际 医院集团 西南合成 制药股份 有限公司	制证完毕 - 已发批 件	2016-01-14	批准临床
CXHS13 00064	甲磺酸伊 马替尼	新药	3.1	2013- 09-09	海南锦瑞 制药有限 公司	制证完毕 - 已发批 件	2016-01-14	批准临床
CXHS13 00179	甲磺酸伊 马替尼	新药	3.1	2013- 09-11	福建南方 制药股份 有限公司	制证完毕 - 已发批 件	2015-12-30	批准临床
CYHS13 01018	甲磺酸伊 马替尼片	仿制	6	2013- 09-17	北大国际 医院集团 西南合成 制药股份 有限公司	制证完毕 - 已发批 件	2016-01-14	批准临床
CYHS13 00263	甲磺酸伊 马替尼胶 囊	仿制	6	2013- 09-22	山东齐都 药业有限 公司	制证完毕 - 已发批 件	2016-01-14	批准临床
CYHS13 00651	甲磺酸伊 马替尼片	仿制	6	2013- 09-27	南京优科 制药有限 公司	制证完毕 - 已发批 件	2016-01-13	批准临床
CXHS13	甲磺酸伊	新药	3.1	2013-	齐鲁天和 惠世制药	制证完毕 - 已发批	2016-04-07	

00254	马替尼			09-29	有限公司	件		
JXHS13 00076	甲磺酸伊 马替尼	进口		2013- 10-11	天津青松 华药医药 有限公司	在审评	2013-10-09	
JYHB13 01233	甲磺酸伊 马替尼片	补充申请		2013- 10-12	北京诺华 制药有限 公司	制证完毕 - 已发批 件	2014-08-27	
CYHS13 90066	甲磺酸伊 马替尼片	仿制	6	2013- 10-12	齐鲁制药 (海南)有 限公司	制证完毕 - 已发批 件	2016-03-10	企业撤回
CYHS13 90065	甲磺酸伊 马替尼片	仿制	6	2013- 10-12	齐鲁制药 (海南)有 限公司	制证完毕 - 已发批 件	2016-03-10	企业撤回
CXHS13 00198	甲磺酸伊 马替尼	新药	3.1	2013- 12-17	湖北葛店 人福药业 有限责任 公司	制证完毕 - 已发批 件	2016-01-22	批准临床
CYHS13 90086	甲磺酸伊 马替尼胶 囊	仿制	6	2013- 12-18	重庆市庆 余堂制药 有限公司	制证完毕 - 已发批 件	2016-02-04	企业撤回
CYHS13 90085	甲磺酸伊 马替尼片	仿制	6	2013- 12-18	重庆市庆 余堂制药 有限公司	制证完毕 - 已发批 件	2016-02-04	企业撤回
CXHS13 00316	甲磺酸伊 马替尼	新药	3.1	2013- 12-20	福安药业 (集团) 股份有限 公司	制证完毕 - 已发批 件	2016-01-29	
CYHS13 00536	甲磺酸伊 马替尼片	仿制	6	2013- 12-27	北京双鹭 药业股份 有限公司	制证完毕 - 已发批 件	2016-01-21	批准临床
CYHS13 00533	甲磺酸伊 马替尼片	仿制	6	2013- 12-27	北京双鹭 药业股份 有限公司	制证完毕 - 已发批 件	2016-01-21	批准临床
CXHS13 00346	甲磺酸伊 马替尼	新药	3.1	2014- 01-03	南京先声 东元制药 有限公司	制证完毕 - 已发批 件	2016-08-23	
CYHS13 90091	甲磺酸伊 马替尼片	仿制	6	2014- 01-03	南京先声 东元制药 有限公司	制证完毕 - 已发批 件	2016-03-10	企业撤回
CYHS13 01587	甲磺酸伊 马替尼片	仿制	6	2014- 02-19	深圳万乐 药业有限 公司	制证完毕 - 已发批 件	2015-12-24	
CYHS13 01025	甲磺酸伊 马替尼片	仿制	6	2014- 02-20	福建南方 制药股份 有限公司	制证完毕 - 已发批 件	2016-01-22	批准临床

CYHS13 01553	甲磺酸伊 马替尼胶 囊	仿制	6	2014- 02-24	亿腾药业 (泰州) 有限公司	制证完毕 - 已发批 件	2016-09-28	批准临床
CYHS13 01552	甲磺酸伊 马替尼片	仿制	6	2014- 02-24	亿腾药业 (泰州) 有限公司	制证完毕 - 已发批 件	2016-09-26	批准临床
CYHS13 01551	甲磺酸伊 马替尼	仿制	6	2014- 02-24	亿腾药业 (泰州) 有限公司	在审评	2014-02-21	
JYHB05 00197	甲磺酸伊 马替尼片	补充申请		2005- 04-21	北京诺华 制药有限 公司	已发件	2005-09-21	批准补充
JYHB05 00196	甲磺酸伊 马替尼片	补充申请		2005- 04-21	北京诺华 制药有限 公司	已发通知 件	2005-09-21	批准补充
JYHB14 00479	甲磺酸伊 马替尼片	补充申请		2014- 04-14	北京诺华 制药有限 公司	制证完毕 - 已发批 件	2014-12-04	
JYHB14 00478	甲磺酸伊 马替尼片	补充申请		2014- 04-14		制证完毕 - 已发批 件	2014-10-28	
CYHS14 00137	甲磺酸伊 马替尼	仿制	6	2014- 06-09	四川协力 制药有限 公司	在审评	2014-06-06	
JXHS14 00038	甲磺酸伊 马替尼	进口		2014- 07-02	北京万全 阳光医学 技术有限 公司	在审评	2014-07-01	
JYHZ14 00413	甲磺酸伊 马替尼片	进口再注 册		2014- 07-10	北京诺华 制药有限 公司	制证完毕 - 已发批 件	2015-06-01	
JYHZ14 00412	甲磺酸伊 马替尼胶 囊	进口再注 册		2014- 07-10	北京诺华 制药有限 公司	制证完毕 - 已发批 件	2015-05-28	
CYHS13 02204	甲磺酸伊 马替尼片	仿制	6	2014- 08-20	福建天泉 药业股份 有限公司	制证完毕 - 已发批 件	2016-02-04	批准临床
CXHS13 00415	甲磺酸伊 马替尼	新药	3.1	2014- 08-20	福建天泉 药业股份 有限公司	制证完毕 - 已发批 件	2016-02-04	批准临床
CYHS14 00597	甲磺酸伊 马替尼片	仿制	6	2014- 08-20	珠海联邦 制药股份 有限公司 中山分公 司	制证完毕 - 已发批 件	2016-02-18	批准临床
					珠海联邦			

CYHS14 00596	甲磺酸伊 马替尼片	仿制	6	2014- 08-20	制药股份 有限公司 中山分公 司	制证完毕 - 已发批 件	2016-02-18	批准临床
JXHL14 00282	甲磺酸伊 马替尼片	进口		2014- 09-02	韩美药品 株式会社	在审评	2014-09-01	
CYHS14 01121	甲磺酸伊 马替尼片	仿制	6	2014- 10-22	重庆药友 制药有限 责任公司	制证完毕 - 已发批 件	2016-10-11	批准临床
JXHL14 00372	甲磺酸伊 马替尼片	进口		2014- 11-13	北京万全 阳光医学 技术有限 公司	在审评	2014-11-05	
CYHS14 01167	甲磺酸伊 马替尼	仿制	6	2014- 11-28	陕西大生 制药科技 有限公司	在审评	2014-11-26	
CYHS14 01168	甲磺酸伊 马替尼胶 囊	仿制	6	2014- 11-28	西安葛蓝 新通制药 有限公司	制证完毕 - 已发批 件	2016-10-18	批准临床
JXHL14 00371	甲磺酸伊 马替尼片	进口		2014- 12-18	北京万全 阳光医学 技术有限 公司	在审评	2014-12-16	
JXHL14 00394	甲磺酸伊 马替尼胶 囊	进口		2014- 12-23	上海礼易 医药科技 有限公司	制证完毕 - 已发批 件	2016-07-25	
CYHS14 00320	甲磺酸伊 马替尼	仿制	6	2015- 01-14	苏州立新 制药有限 公司	在审评	2015-01-08	
CYHS14 00370	甲磺酸伊 马替尼片	仿制	6	2015- 01-23	江苏正大 清江制药 有限公司	制证完毕 - 已发批 件	2016-10-11	批准临床
CYHS14 00369	甲磺酸伊 马替尼	仿制	6	2015- 01-23	江苏正大 清江制药 有限公司	在审评	2015-01-21	
CYHS14 01894	甲磺酸伊 马替尼	仿制	6	2015- 03-03	重庆芸峰 药业有限 公司	在审评	2015-02-28	
CYHS14 01895	甲磺酸伊 马替尼片	仿制	6	2015- 03-03	重庆芸峰 药业有限 公司	制证完毕 - 已发批 件	2016-10-11	批准临床
CYHS14 01032	甲磺酸伊 马替尼	仿制	6	2015- 03-13	广州南沙 龙沙有限 公司	在审评	2015-03-10	
CYHS15 90014	甲磺酸伊 马替尼胶	仿制	6	2015- 04-03	江苏万高 药业有限	制证完毕 - 已发批	2017-03-01	企业撤回

	囊				公司	件		
CYHS14 02074	甲磺酸伊 马替尼片	仿制	6	2015- 05-08	重庆莱美 药业股份 有限公司	制证完毕 - 已发批 件	2016-10-24	批准临床
CYHS14 02073	甲磺酸伊 马替尼	仿制	6	2015- 05-08	重庆莱美 药业股份 有限公司	在审评	2015-05-05	
CXHS15 00011	甲磺酸伊 马替尼	新药	3.1	2015- 05-29	浙江九洲 药业股份 有限公司	制证完毕 - 待发批 件	2017-04-06	
JYHB15 01253	甲磺酸伊 马替尼片	补充申请		2015- 09-08	北京诺华 制药有限 公司	制证完毕 - 已发批 件	2016-08-01	
JYHB15 01248	甲磺酸伊 马替尼胶 囊	补充申请		2015- 09-08	北京诺华 制药有限 公司	制证完毕 - 已发批 件	2016-08-01	
JYHB15 01252	甲磺酸伊 马替尼片	补充申请		2015- 09-08	北京诺华 制药有限 公司	制证完毕 - 已发批 件	2016-08-01	
CYHS13 00970	甲磺酸伊 马替尼片	仿制	6	2015- 10-08	辰欣药业 股份有限 公司	制证完毕 - 已发批 件	2016-08-01	批准临床
CXHS13 00168	甲磺酸伊 马替尼	新药	3.1	2015- 10-08	辰欣药业 股份有限 公司	制证完毕 - 已发批 件	2016-08-01	批准临床
CYHB15 10377	甲磺酸伊 马替尼	补充申请		2015- 12-24	连云港宏 创药业有 限公司	在审评	2015-12-22	
JXHL16 00005	甲磺酸伊 马替尼胶 囊	进口		2016- 01-31	联合生物 技术私人 有限公司	在审评	2016-01-29	
CYHS15 00273	甲磺酸伊 马替尼	仿制	6	2016- 05-03	连云港杰 瑞药业有 限公司	在审评	2016-04-29	
CYHB16 02551	甲磺酸伊 马替尼片	补充申请		2016- 08-29	江苏豪森 药业集团 有限公司	制证完毕 - 已发批 件	2017-03-29	

## 药品标准(4条)

序号	药品名称	标准来源	页码	查看全文/文件下载
1	甲磺酸伊马替尼胶囊(格列卫)	进口药品复核标准汇编2002年		<a href="#">查看</a>
2	甲磺酸伊马替尼片	JX20040087		
3	甲磺酸伊马替尼胶囊	JX20090274		

4	Imatinib Mesylate	IP2010	1484	<a href="#">查看</a>
---	-------------------	--------	------	--------------------

## 药品说明书(19条)

[查看全部](#)

序号	药品名称	来源	更新时间	操作
1	格列卫GLEEVEC(甲磺酸伊马替尼imatinib mesylate)口服片			<a href="#">查看全文</a>
3	甲磺酸伊马替尼胶囊	NovartisPharmaSchweizAG		<a href="#">查看全文</a>
5	イマチニブ錠100mg 「テバ」	製造販売:武田テバファーマ/販売:武田薬品工業/		<a href="#">查看</a>
6	イマチニブ錠100mg 「サワイ」,イマチニブ錠200mg 「サワイ」	製造販売:沢井製薬/		<a href="#">查看</a>
7	イマチニブ錠200mg 「ヤクルト」	製造販売:高田製薬/発売:ヤクルト本社/		<a href="#">查看</a>
8	イマチニブ錠100mg 「ニプロ」	製造販売:ニプロ/販売:共和クリティケア/		<a href="#">查看</a>
9	イマチニブ錠100mg 「ケミファ」	製造販売:日本ケミファ/		<a href="#">查看</a>
10	イマチニブ錠100mg 「オーハラ」	製造販売:大原薬品工業/		<a href="#">查看</a>
11	イマチニブ錠100mg 「明治」,イマチニブ錠200mg 「明治」	製造販売:MeijiSeikaファルマ/		<a href="#">查看</a>
12	イマチニブ錠100mg 「NSKK」	製造販売:共創未来ファーマ/販売:日本新薬/		<a href="#">查看</a>
13	イマチニブ錠100mg 「DSEP」	製造販売:第一三共エスファ/		<a href="#">查看</a>
14	イマチニブ錠100mg 「ニプロ」,イマチニブ錠200mg 「ニプロ」	製造販売:ニプロ/		<a href="#">查看</a>
15	イマチニブ錠100mg 「NK」	製造販売:日本化薬/		<a href="#">查看</a>
16	イマチニブ錠100mg 「ヤクルト」	製造販売:高田製薬/発売:ヤクルト本社/		<a href="#">查看</a>
17	イマチニブ錠100mg 「KN」	製造販売:小林化工/		<a href="#">查看</a>
18	イマチニブ錠100mg 「EE」	製造販売:エルメッドエーザイ/		<a href="#">查看</a>
19	グリベック錠100mg	製造販売:ノバルティスファーマ/		<a href="#">查看</a>

## 全球临床试验情况(305条)

[隐藏](#)

序号	注册题目	招募状态	试验分期	国家	登记时间
	<a href="#">Safety and Efficiency Study of Pioglitazone in Combination</a>	Not yet			2016-



1	With Imatinib Mesylate to Treat Chronic Myelogenous Leukemia	recruiting	Phase 2		01-27
2	Comparative study for Imatinib Mesylate 400mg tablets of Sponsor with Imatinib Mesylate 400mg tablets of (Gleevec®)Novartis Pharmaceuticals Corporation, New Jersey in patients with Chronic Myeloid Leukemia and/or Gastrointestinal Stromal Tumor under fed	Recruiting		India	2015-02-06
3	A bioequivalence study of Imatinib Mesylate Tablets 400 mg of Intas Pharmaceuticals Limited, India to the reference listed drug Gleevec® (Imatinib Mesylate) Tablets 400 mg in patients of Chronic Myeloid Leukaemia (CML)			India	2014-12-30
4	Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia	Not yet recruiting	Phase 4		2014-12-11
5	Combination of Gemcitabine and Imatinib Mesylate in Pemetrexed-pretreated Patients With Pleural Mesothelioma	Recruiting	Phase 2	Italy	2014-11-19
6	Comparative study for Imatinib Mesylate 400mg tablets of Sponsor with Imatinib Mesylate 400mg tablets of (Gleevec®)Novartis Pharmaceuticals Corporation, New Jersey in patients with Chronic Myeloid Leukemia and/or Gastrointestinal Stromal Tumor under fed			India	2014-11-03
7	BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)	Recruiting	Phase 1/Phase 2	United States	2014-10-02
8	Pharmacokinetics of very low single-dose Imatinib Mesylate (Gleevec) to healthy Chinese male volunteers in an open-label Phase 0 clinical study			China	2014-09-30

9	Study of Imatinib Mesylate in Neurofibromatosis Type I Patients Aged 2 to 21 With Plexiform Neurofibromas	Recruiting	Phase 2	Canada	2014-06-25
10	Comparative study for Imatinib Mesylate 400mg tablets of Sponsor with Imatinib Mesylate 400mg tablets of (Gleevec®)Novartis Pharmaceuticals Corporation, New Jersey in patients with Chronic Myeloid Leukemia and/or Gastrointestinal Stromal Tumor under fed			India	2014-06-05
11	Comparative study for Imatinib Mesylate 400mg tablets of Sponsor with Imatinib Mesylate 400mg tablets of (Gleevec®)Novartis Pharmaceuticals Corporation, New Jersey in patients with Chronic Myeloid Leukemia and/or Gastrointestinal Stromal Tumor under fed			India	2014-06-05
12	Comparative Bioequivalence Study in Adult Patients Suffering From Chronic Myeloid Leukemia & Gastrointestinal Stromal Tumor Under Fed Conditions	Completed	Phase 2/Phase 3	India	2014-04-01
13	A study to monitor the safety and to assess the steady-state bioequivalence of Imatinib Mesylate 400 mg tablets of Sun Pharmaceutical Industries Ltd, India in Chronic Myeloid Leukemia (CML) patients	Recruiting		India	2014-03-19
14	Bioequivalence study of imatinib mesylate tablets in patients of chronic myeloid leukemia and gastrointestinal stromal tumor			India	2014-02-07
15	MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)	Recruiting	Phase 1/Phase 2	United States	2013-11-18
16	A Clinical trial intended to compare two formulations of Imatinib 400mg. tablets, in Patients with Gastrointestinal Stromal Tumors or Chronic			India	2013-10-07

	Myeloid Leukemia				
17	Comparison of two Imatinib Mesylate tablets in patients of Philadelphia chromosome positive Chronic Myeloid Leukaemia, stabilized on Imatinib Mesylate tablets 400mg			India	2013-09-27
18	to Evaluate the Pharmacokinetics(Cmax, Auc) of CJ Imatinib Mesylate Tablet 200mg x 1 Compared With Gleevec Film-coated Tablet 100mg x 2 in Healthy Male Volunteers	Completed	Phase 1	Korea, Republic of	2013-08-14
19	Comparison of two Imatinib Mesylate tablets in patients of Philadelphia chromosome positive Chronic Myeloid Leukaemia stabilized on Imatinib Mesylate tablets 400mg			India	2013-07-24
20	to assess the safety and tolerability of Imatinib following oral administration of Test and Reference products during the study			India	2013-06-13
21	Imatinib Mesylate and Mycophenolate Mofetil for Steroid-Refractory Sclerotic/Fibrotic cGVHD in Children	Recruiting	Phase 2	Korea, Republic of	2013-06-05
22	Effect of Imatinib Mesylate in patients undergone allogeneic bone marrow transplantation who show chronic coetaneous involvement Graft Versus-Host Disease.		phase 2	Iran, Islamic Republic Of	2013-06-03
23	Pharmacokinetics of Imatinib mesylate tablet 200mg		phase 1	Korea, Republic of	2013-05-29
24	This is comparative study for the Imatinib Mesylate 400mg tablets with Imatinib Mesylate 400mg tablets of (GLIVEC®)Novartis Europharm Limited, United Kingdom in patients with Chronic Myeloid Leukemia and/or Gastrointestinal Stromal Tumor under fed steady			India	2013-04-11

25	This is comparative study for the Imatinib Mesylate 400mg tablets with Imatinib Mesylate 400mg tablets of (Gleevec)Novartis Pharmaceuticals Corporation, East Hanover, New Jersey in patients with Chronic Myeloid Leukemia and/or Gastrointestinal Stromal Tu			India	2013-02-26
26	A short duration interview based study conducted on the Chronic Myeloid Leukemia patients at single site in order to determine the compliance / adherence to their medication Imatinib Mesylate and to find out the factors causing the non compliance / non ad			India	2013-02-25
27	A Clinical Trial to Compare the Pharmacokinetics of Imatinib Mesylate Tablet 400mg (1 Tablet) and Glivec Film-coated Tablet 100mg (4 Tablets)(Phase I)	Completed	Phase 1	Korea, Republic of	2012-12-14
28	Ipilimumab and Imatinib Mesylate in Advanced Cancer	Recruiting	Phase 1	United States	2012-11-28
29	Phase III Trial Evaluating the Effectiveness of a Dose Adjustment of Imatinib Mesylate on the Molecular Response	Recruiting	Phase 3	France	2012-11-05
30	Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas	Completed	Phase 2	United States	2012-08-22
31	Megavec 400 mg (Imatinib Mesylate) in Healthy Adult Male Volunteers	Completed	Phase 1		2012-07-25
32	Telemonitoring Study - for Chronic Myeloid Leukemia (CML)	Completed		United States	2011-12-08
33	Phase II Study of Imatinib Mesylate for the Neoadjuvant Treatment of Patients With Gastrointestinal Stromal Tumors (GIST)	Completed	Phase 2	Brazil	2011-11-29
	Pilot Study to Assess				

34	Telemonitoring of Gleevec (Imatinib Mesylate) or Tasigna (Niltinib) Therapy	Active, not recruiting		United States	2011-10-14
35	Dasatinib and Cyclosporine in Treating Patients With Chronic Myelogenous Leukemia Refractory or Intolerant to Imatinib Mesylate	Terminated	Phase 1	United States	2011-08-30
36	Entinostat And Imatinib Mesylate In Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia	Terminated	Phase 1/Phase 2	United States	2011-05-05
37	Localized gastrointestinal stromal tumors (GIST): an exploratory open-label, multicenter, single-arm phase II study to evaluate the efficacy of 2 years of adjuvant nilotinib treatment following at least 1 year of adjuvant imatinib mesylate	Ongoing	phase 2	Germany	2011-03-30
38	Gleevec as Maintenance Therapy After Cytogenetic Response With Nilotinib in Newly Diagnosed Chronic Myelogenous Leukemia	Recruiting		Lebanon	2011-02-24
39	Everolimus in Combination With Imatinib Mesylate in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Soft Tissue Sarcoma	Completed	Phase 1/Phase 2	United States	2011-01-21
40	Perioperative Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor	Completed	Phase 2	China	2010-12-27
41	Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+)	Suspended	Phase 2		2010-10-15
42	An Open-Label, Phase II Study to Evaluate the Biological Activity of AZD2171, as Measured by FDG-PET Response, in Patients with Metastatic Gastro-Intestinal Stromal Tumours (GIST) Resistant or Intolerant to	Ongoing	phase 2	United Kingdom	2010-10-14

	Imatinib Mesylate.				
43	Phase II Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Chronic Myeloid Leukemia (CML) Philadelphia Chromosome-positive (Ph+)	Active, not recruiting	Phase 2	Brazil	2010-10-14
44	Imatinib mesylate versus allogeneic HSCT for patients with chronic myelogenous leukemia			China	2010-07-24
45	Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas	Active, not recruiting	Phase 1/Phase 2	United States	2010-06-08
46	Study to Evaluate Imatinib in Desmoid Tumors	Active, not recruiting	Phase 2	Germany	2010-06-02
47	Safety of Zileuton (Zyflo) in Combination With Imatinib Mesylate (Gleevec) in CML.	Terminated	Phase 1	United States	2010-05-24
48	A prospective randomized phase II study evaluating the monitoring of imatinib mesylate (Glivec®) plasmatic through level in patients newly diagnosed with chronic phase chronic myelogenous leukaemia (CP-CML). - OPTIM IMATINIB	Ongoing	phase 2	France	2010-05-06
49	A Study of Imatinib With Reinduction Chemotherapy Using Mitoxantrone, Etoposide and Cytarabine in Patients With Relapsed/Refractory C-kit Positive (AML) Acute Myeloid Leukemia	Completed	Phase 1/Phase 2	Canada	2010-05-03
50	Surgery versus no surgery of residual disease in patients with metastatic gastro-intestinal stromal tumour	Recruiting		Australia;France;Germany;Italy;Netherlands;New Zealand;Spain;United Kingdom	2010-04-29
51	Imatinib Mesylate and Docetaxel in Non-Small Cell Lung Cancer (NSCLC)	Completed	Phase 2	United States	2010-03-08
52	Evaluation of the safety and efficacy of Imatinib in Pat. with Desmoid-Tumors	Completed	phase 2	Germany	2010-03-02
	Discontinuation of Imatinib				

53	Mesylate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With Interferon-Alpha	Terminated		United States	2010-02-19
54	Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders.	Terminated	Phase 1	Russian Federation;United States;Canada;France;Germany;Hungary;Netherlands;Russian Federation	2010-02-09
55	Trial of Tasigna (Nilotinib) 400 mg Twice Daily Alone or With Gleevec (Imatinib Mesylate) 400 mg Daily for Patients With Advanced Gastrointestinal Stromal Tumor (GIST)	Terminated	Phase 2	United States	2010-01-28
56	Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib Mesylate	Completed	Phase 1	France	2010-01-11
57	Gemcitabine and Oxaliplatin (Gem-Ox) Plus Glivec in Gemcitabine-refractory Pancreatic Cancer	Completed	Phase 1	United Kingdom	2010-01-11
58	Autologous Transplantation for Chronic Myelogenous Leukemia	Completed	Phase 2	United States	2009-10-26
59	Study of Gleevec and Weekly Paclitaxel in Patients Aged 70 or Older With Advanced Non-small Cell Lung Cancer	Completed	Phase 2	United States	2009-10-14
60	Treatment of Patients With Nephrogenic Systemic Fibrosis With Glivec	Completed	Phase 3	Denmark	2009-09-21
61	Imatinib In Adjuvant GIST		Phase 2	India	2009-09-09
62	A clinical trial to study the safety and efficacy of NRC-AN-019 in patients with chronic Myeloid Leukemia who are not responding or intolerant to Imatinib mesylate		Phase 1	India	2009-08-21
63	A phase III randomized study evaluating surgery of residual disease in patients with metastatic gastro-intestinal stromal tumor responding to imatinib mesylate		Phase 3	Australia;New Zealand;New Zealand;Belgium;France;Italy;Belgium	2009-08-10

64	CLAG Gleevec in Relapsed or Refractory Acute Myeloid Leukemia (AML)	Completed	Phase 2	United States	2009-08-05
65	Treatment of patients with Nephrogenic Systemic Fibrosis(NSF) with Imatinib Mesylate(Glivec). An open label clinical trial among patients with moderate to severe NSF.	Completed	phase 2	Denmark	2009-07-21
66	Étude multicentrique de phase III évaluant L' efficacité d' une stratégie d' adaptation de dose de l' imatinib mésylate sur la réponse moléculaire chez des patients présentant une leucémie myéloïde chronique en phase chronique traités par imatinib mésylate 40	Ongoing	phase 3	France	2009-06-09
67	Hydroxyurea With or Without Imatinib Mesylate in Treating Patients With Recurrent or Progressive Meningioma	Recruiting	Phase 2	Italy	2009-05-19
68	A PHASE II STUDY TO ASSESS EFFICACY AND SAFETY OF PIOGLITAZONE (ACTOS®) AS ADD-ON THERAPY TO IMATINIB MESYLATE (GLEEVEC®) IN CHRONIC PHASE CHRONIC MYELOGENOUS LEUKAEMIA (CP-CML) PATIENTS IN MAJOR MOLECULAR RESPONSE (MMR). - ACTIM	Ongoing	phase 2	France	2009-04-30
69	Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)	Active, not recruiting	Phase 2	United States	2009-03-20
70	Docetaxel (Taxotere) and Imatinib Mesylate (Gleevec) in Hormone Refractory Prostate Cancer	Terminated	Phase 1/Phase 2	United States	2009-03-12
71	Imatinib Mesylate (Gleevec) and Paclitaxel in Recurrent Patients of Ovarian and Other Cancers of Mullerian Origin	Terminated	Phase 2	United States	2009-02-09
72	Glivec (imatinib mesylate) in systemic sclerosis, a pilot study.	Recruiting		The Netherlands	2008-12-01
	Safety And Efficacy Study Of Sunitinib Malate In Chinese				



73	Patients With Imatinib Resistant Or Intolerant Malignant Gastrointestinal Stromal Tumor	Completed	Phase 4	China	2008-11-17
74	A phase III randomized study evaluating surgery of residual disease in patients with metastatic gastro-intestinal stromal tumor responding to Imatinib mesylate.	Prematurely Ended	phase 3	United Kingdom;Netherlands;France;Italy	2008-10-31
75	Phase II monitored clinical trial for evaluation of treatment of patients with Thymic Epithelial Tumours (TET) or Histiocytosis X (LCH) with Imatinib Mesylate. - TETIMAX	Ongoing	phase 2	Italy	2008-10-01
76	Imatinib Mesylate in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal Tumor	Active, not recruiting	Phase 2	Japan	2008-10-01
77	A Pilot Study of Imatinib Mesylate in Steroid Refractory Chronic Graft Versus Host Disease	Active, not recruiting	Phase 1	United States	2008-09-25
78	Imatinib + MTC in Relapsed / Refractory Acute Myeloid Leukemia (AML)	Recruiting	Phase 2	Germany	2008-08-28
79	Effect of Calcium on Gleevec Pharmacokinetics (PK) in Healthy Volunteers	Completed	Phase 1	United States	2008-08-07
80	Imatinib Mesylate With Vincristine and Dexamethasone in Acute Lymphoblastic Leukemias With BCR-ABL Positive	Completed	Phase 2	France	2008-07-25
81	An open-label, multicenter, expanded access study of imatinib mesylate in adult patients with GIST in adjuvant setting after R0-resection	Completed	phase 3	France;Hungary;Czech Republic;Belgium;Spain;Germany;Italy	2008-07-24
82	Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia	Completed	Phase 1/Phase 2	United States	2008-06-19
83	Imatinib Mesylate to Treat Skin Changes in Patients With Chronic Graft-Versus-Host Disease	Completed	Phase 2	United States	2008-06-19

84	Panobinostat (LBH589) and Imatinib Mesylate in Treating Patients With Previously Treated Chronic Phase Chronic Myelogenous Leukemia	Completed	Phase 1	United States	2008-05-28
85	Gleevec in Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma	Completed		United States	2008-05-22
86	Imatinib Mesylate in Treating Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumor	Active, not recruiting	Phase 3		2008-05-22
87	Pilot Study of Imatinib Mesylate to Treat Nephrogenic Systemic Fibrosis	Active, not recruiting	Phase 2	United States	2008-05-08
88	Study of Temzolomide and Gleevec in Advanced Melanoma	Completed	Phase 1/Phase 2	United States	2008-04-24
89	IMATINIB MESYLATE IN ADVANCED LOW GRADE SOLID TUMORS EXPRESSING IMATINIB MESYLATE TARGETS - ND	Ongoing	phase 2	Italy	2008-04-22
90	A phase II study of the association of Glivec (imatinib mesylate, formerly known as STI 571) plus Gemzar (gemcitabine) in patients with unresectable, refractory, malignant mesothelioma expressing either PDGFR-beta or C-Kit. - ND	Completed	phase 2	Italy	2008-03-10
91	Imatinib Mesylate and Combination Chemotherapy With or Without a Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia	Completed	Phase 2	Korea, Republic of	2008-02-19
92	Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG)	Completed	Phase 2	United States	2008-02-03
93	Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma	Completed	Phase 1	United States	2008-01-29
	Efficacy and Tolerability of			United States;Germany;Italy;	

94	STI571 (Imatinib Mesylate) for the Treatment of Fibrosis in Patients With Systemic Sclerosis	Completed	Phase 2	Switzerland;United Kingdom;United States;Germany;Italy; Switzerland;Unite	2008-01-25
95	A Study Evaluating the Effects of CLAG With Gleevec in Refractory or Relapsed Acute Myeloid Leukemia	Withdrawn	Phase 2	United States	2008-01-03
96	Safety Study of Gleevec® in Children With Pulmonary Hypertension	Terminated	Phase 2	United States	2007-12-20
97	Imatinib Mesylate and Sunitinib in Treating Patients With Gastrointestinal Stromal Tumors	Terminated	Phase 1	United States	2007-12-13
98	Dose Escalation Study of Gleevec and Chlorambucil in Previously Treated Chronic Lymphocytic Leukemia Patients	Terminated	Phase 1/Phase 2	Canada	2007-11-15
99	Imatinib Mesylate (Gleevec) in the Treatment of Systemic Sclerosis	Active, not recruiting	Phase 2	United States	2007-11-07
100	A Phase II Study of the Association of Glivec® Plus Gemzar® in Patients With Unresectable, Refractory, Malignant Mesothelioma	Not yet recruiting	Phase 2	Italy	2007-10-29
101	Phase II study of Glivec (imatinib mesylate) in patients with advanced neuroblastoma - ND	Completed	phase 2	Italy	2007-09-07
102	Imatinib Mesylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Received Chemotherapy	Active, not recruiting	Phase 2	United States	2007-07-30
103	Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients	Terminated	Phase 2	United States	2007-07-10
104	Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer	Completed	Phase 2	United States	2007-07-10
105	Preoperative and Postoperative Imatinib Mesylate Study in Patients With c-Kit Positive GIST	Completed	Phase 2	United States	2007-07-10
106	Imatinib Mesylate (Gleevec) and Docetaxel in Patients With Head and Neck Squamous Cell Cancer	Completed	Phase 2	United States	2007-06-12

107	Imatinib Mesylate, Gemcitabine, and Capecitabine in Treating Patients With Advanced Solid Tumors (Closed to Accrual 12/11/2008)	Active, not recruiting	Phase 1	United States	2007-06-06
108	Efficacy and Safety of Imatinib in Scleroderma	Completed	Phase 2	France	2007-05-29
109	Safety and Efficacy of Imatinib Mesylate in Patients With Pulmonary Arterial Hypertension	Completed	Phase 2/Phase 3	United States;Austria;Germany;United Kingdom;United States;Austria;Germany;United Kingdom	2007-05-22
110	Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery	Completed	Phase 2	United States	2007-05-03
111	A Phase I/II Study of Sunitinib Malate (SU011248) In Patients With Gastrointestinal Stromal Tumor (GIST)	Completed	Phase 1/Phase 2	Japan	2007-04-04
112	Glivec (imatinib mesylate) in systemic sclerosis, a pilot study - Glivec in systemic sclerosis	Ongoing	phase 2	Netherlands	2007-04-02
113	Korean Early Access Program	Approved for marketing		Korea, Republic of	2007-03-30
114	Ph II Study of Perifosine Plus Gleevec for Patients With GIST	Completed	Phase 2	United States	2007-03-30
115	A Phase II, open-label study of PTK787/ZK222584 in the treatment of metastatic gastrointestinal stromal tumors GISTs resistant to imatinib mesylate	Ongoing	phase 2	Italy	2007-03-15
116	Effect of a Proton Pump Inhibitor on Gleevec® in Healthy Volunteers	Completed	Phase 1	United States	2007-03-08
117	Effect of Antacids on Gleevec® in Healthy Volunteers	Completed	Phase 1	United States	2007-03-08
118	A PHASE IIIB, RANDOMIZED, ACTIVE CONTROLLED OPEN-LABEL STUDY OF SUNITINIB (SUTENT®) 37.5 MG DAILY VS IMATINIB MESYLATE 800 MG DAILY IN THE TREATMENT OF PATIENTS WITH GASTROINTESTINAL STROMAL TUMORS (GIST) WHO HAVE		Phase 3	France;Spain;Germany;United Kingdom;Italy	2007-02-28

	HAD PROGRESSIVE DISEASE WHILE ON 400 MG D				
119	Essai clinique de phase II, comparatif, randomisé, en double insu, de l' imatinib mésylate STI571 (Glivec®) versus placebo chez des malades atteints de sclérodémie cutanée grave et de sclérodémie systémique avec atteinte cutanée grave Scléro-Glivec -	Ongoing	phase 2	France	2007-02-12
120	OPEN-LABEL TRIAL OF GLIVEC IMATINIB MESYLATE IN PATIENTS WITH REFRACTORY DESMOPLASTIC SMALL ROUND CELL TUMORS DSRCT EXPRESSING A MOLECULAR TARGET OF GLIVEC PDGF-R AND/OR C-KIT	Completed	phase 2	Italy	2007-02-01
121	Effects of Imatinib Mesylate in Polycythemia Vera	Completed	Phase 2	Italy	2007-01-31
122	Effect of Imatinib Mesylate and the Pharmacokinetics of Acetaminophen/Paracetamol in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP)	Completed	Phase 1	Korea, Republic of	2007-01-29
123	Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors	Terminated	Phase 2/Phase 3	Germany	2007-01-25
124	Imatinib Mesylate and Bevacizumab After First-Line Chemotherapy and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer	Completed	Phase 2	United States	2007-01-19
125	Study Combining Imatinib Mesylate (Gleevec) With Sorafenib in Patients With Androgen-independent Prostate Cancer (AIPC)	Completed	Phase 1	United States	2007-01-17
126	Imatinib Mesylate in Patients With Refractory Desmoplastic Small Round Cell Tumors	Completed	Phase 1/Phase 2	Italy	2007-01-02
	TALL-104 and Gleevec in				2006-

127	Chronic Myelogenous Leukemia Patients	Terminated	Phase 2	United States	12-22
128	Imatinib Mesylate and Paclitaxel in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer	Completed	Phase 2	United States	2006-12-06
129	Imatinib Mesylate Combined With Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration	Withdrawn	Phase 1	United States	2006-11-22
130	Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma	Completed	Phase 1	United States	2006-11-20
131	Tumor Tissue Analysis in Patients Receiving Imatinib Mesylate for Malignant Glioma	Completed		United States	2006-11-16
132	Glivec® (imatinib mesylate)/Litalir® (hydroxyurea) plus initial radiotherapy after surgery in patients with newly diagnosed glioblastoma multiforme followed by Glivec® and Litalir® – A phase I/II safety evaluation study.	Completed	phase 2	Germany	2006-11-14
133	Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid Leukaemia	Completed	Phase 4	Spain	2006-10-20
134	Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma	Completed	Phase 1	United States	2006-10-12
135	Use and Tolerability of Imatinib Mesylate (Gleevec) in Leukemia Patients	Completed		United States	2006-10-09
136	Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors	Terminated	Phase 3	United States;Germany;Hong Kong;Italy;Korea, Republic of;Spain;United Kingdom;United States;Germany;	2006-09-05
137	Interferon and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy	Recruiting	Phase 2	United States;United	2006-

	in Patients With Chronic Phase CML on a TKI			States	08-10
138	A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy	Terminated	Phase 3	United States;Canada	2006-08-09
139	Phase II Trial of Locally Advanced/Metastatic Soft Tissue Sarcoma or Advanced/Metastatic Malignant GIST	Completed	Phase 2	Taiwan	2006-08-01
140	Imatinib Mesylate and Temozolomide in Treating Patients With Malignant Glioma	Completed	Phase 1	United States	2006-07-19
141	Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma	Completed	Phase 2	United States	2006-07-19
142	Imatinib in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma	Terminated	Phase 1/Phase 2	United States	2006-07-18
143	Letrozole (Femara) Plus Imatinib Mesylate (Gleevec) for Breast Cancer Patients	Active, not recruiting	Phase 2	United States	2006-06-16
144	PHA-739358 in Treating Patients With Chronic Myelogenous Leukemia That Relapsed After Imatinib Mesylate or c-ABL Therapy	Active, not recruiting	Phase 2	United States	2006-06-08
145	Everolimus and Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer	Completed	Phase 2	United States	2006-05-30
146	Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor	Completed	Phase 3	United States;Canada;United States;Canada	2006-05-10
147	Gemcitabine +/- Imatinib Mesylate, Patients w/Previously Treated Metastatic Breast Cancer	Active, not recruiting	Phase 2	United States	2006-05-08
	Gemcitabine With or Without				

148	Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer	Terminated	Phase 2	United States	2006-05-08
149	Reduced intensity chemotherapy given with and without Imatinib Mesylate in patients $\geq 60$ years considered unfit for standard chemotherapy with previously untreated Acute Myeloid Leukemia (AML) and refractory anemia with excess of Blasts (RAEB, RAEB-T)			The Netherlands	2006-05-01
150	Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate	Completed	Phase 1	United States;Canada	2006-04-19
151	Vaccine Therapy and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia	Active, not recruiting	Phase 1	United States	2006-03-08
152	Gemcitabine and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic Non-Small Cell Lung Cancer	Terminated	Phase 2	United States	2006-03-07
153	A Study of Dasatinib in Patients With Chronic Myelogenous Leukemia Who Are Resistant or Intolerant of Imatinib Mesylate	Completed	Phase 2	United States;Canada;United States;Canada	2006-03-02
154	Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)	Terminated	Phase 2	United States	2006-02-10
155	Imatinib Mesylate in Treating Patients With Recurrent or Refractory Fibromatosis	Recruiting	Phase 1/Phase 2	France	2006-02-06
156	Imatinib Mesylate and Gemcitabine in Treating Patients With Locally Advanced, Metastatic, or Recurrent Pancreatic Cancer	Terminated	Phase 1	United States	2006-01-24
157	Adjuvant Imatinib in High-risk Gastrointestinal Stromal Tumor (GIST) With C-kit Mutation	Completed	Phase 2	Korea, Republic of	2006-01-17



158	An open-label multicenter phase II study of Imatinib mesylate (Glivec) treatment of patients with malignant peripheral nerve sheath tumors	Prematurely Ended	phase 2	Germany	2006-01-17
159	Imatinib Mesylate, Daunorubicin, and Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia	Completed	Phase 1	United States	2005-12-20
160	Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate	Active, not recruiting	Phase 2	United States	2005-12-14
161	Efficacy and Safety of Oral AMN107 in Adults With Chronic Myelogenous Leukemia Resistant and/or Intolerant to Imatinib Mesylate Therapy	Completed	Phase 2/Phase 3	Israel	2005-12-09
162	Phase II study of imatinib mesylate for treatment of Philadelphia Chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in children: A Japanese Cooperative Trial	No longer recruiting	Phase 2	Japan;Japan	2005-12-01
163	Cladribine, Cytarabine, and Imatinib Mesylate in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Blastic Phase Chronic Myelogenous Leukemia	Completed	Phase 1	United States	2005-11-22
164	Evaluate the Efficacy of AMG 706 to Treat Advanced Gastrointestinal Stromal Tumors	Completed	Phase 2	Japan	2005-11-14
165	Imatinib Mesylate and Capecitabine in Treating Patients With Advanced Solid Tumors	Completed	Phase 1	United States	2005-11-11
166	Adjuvant GIST Trial		Phase 3	Australia	2005-11-04
167	Imatinib Mesylate After Irinotecan and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer	Completed	Phase 2	United States	2005-11-03

168	Imatinib Mesylate in Treating Patients With Myelofibrosis	Terminated	Phase 2	United States	2005-10-25
169	Imatinib Mesylate After a Donor Stem Cell Transplant in Treating Patients With Philadelphia Chromosome-Positive Leukemia	Completed	Phase 1/Phase 2	United States	2005-10-25
170	Neoadjuvant Imatinib in Dermatofibrosarcoma Protuberans	Completed	Phase 2	United States	2005-10-20
171	A Study of the Efficacy and Safety of Imatinib Mesylate in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing C-kit Gene	Completed	Phase 2	United States;Australia;Finland;United States;Australia;Finland	2005-10-09
172	Phase II Clinical Study of Imatinib Mesylate in Patients With Malignant Gastrointestinal Stromal Tumors (Extension Study)	Completed	Phase 2		2005-10-09
173	Open-label trial of imatinib mesylate (Glivec, formerly known as STI571) in combination with vinorelbine (Navelbine) for patients with advanced breast carcinoma - ICON	Completed	phase 2	Germany	2005-10-07
174	Phase II Gleevec Idiopathic Hypereosinophilic Syndrome	Withdrawn	Phase 2	United States	2005-09-28
175	Phase II Trial of Gleevec and Taxotere as a Combined Regimen for Advanced Gastric Adenocarcinoma	Terminated	Phase 2	United States	2005-09-14
176	Post-Marketing Clinical Study of Postoperative Adjuvant Therapy With Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors (GIST)	Completed	Phase 4	Japan	2005-09-13
177	A Study to Determine the Safety and Efficacy of Imatinib Mesylate in Patients With Idiopathic Hypereosinophilic Syndrome	Terminated	Phase 2	Belgium	2005-09-13
178	Open-label Trial of Imatinib Mesylate in Patients With Unresectable Recurrent Glioblastoma Multiforme Expressing PDGFR (Platelet	Suspended	Phase 2	Brazil	2005-09-13

	Derived Growth Factor Receptors)				
179	Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML)	Completed	Phase 4	Canada	2005-09-13
180	Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes	Completed	Phase 2	Australia	2005-09-13
181	An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Patients (Male or Female =18 Years) With Ph + CML in Blast Crisis	Completed	Phase 2	United States;France;Germany;Italy;United States;France;Germany;Italy;United Kingdom	2005-09-12
182	A Phase II study to investigate the effect of Glivec® (imatinib mesylate, formerly known as STI571) in patients with inoperable medullary thyroid carcinoma.			The Netherlands	2005-09-12
183	An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Adult Patients With Ph + Leukemia	Completed	Phase 2	United States;France;Germany;Italy;Switzerland; United Kingdom;United States;France;Germany;Italy;Swi	2005-09-12
184	Imatinib Mesylate and Zoledronic Acid in Patients With Chronic Myeloid Leukaemia in Cytogenetic Response Without Molecular Response	Terminated	Phase 2	France	2005-09-12
185	An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Adult Patients With Ph + Leukemia	Completed	Phase 2	United States;France;Germany;Italy;United Kingdom;United States;France;Germany;Italy;United Kingdom	2005-09-12
186	Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian Cancer	Completed	Phase 2	United States	2005-09-12
	Docetaxel Plus Imatinib				

187	Mesylate in Metastatic Breast Cancer	Completed	Phase 2	United States	2005-09-12
188	Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma	Completed	Phase 3	Germany	2005-09-09
189	Efficacy Study of Imatinib Mesylate to Treat Philadelphia-Positive Acute Lymphocytic Leukemia	Completed	Phase 2		2005-09-09
190	Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases	Completed	Phase 2		2005-09-09
191	Gemcitabine and Imatinib Mesylate as First-Line Therapy in Patients With Locally Adv. or Metastatic Pancreatic Cancer	Completed	Phase 2	United States	2005-09-08
192	Efficacy and Safety of Imatinib in Chordoma	Completed	Phase 2	Italy;Switzerland;Italy ;Switzerland	2005-09-07
193	Gleevec Maintenance Therapy After Induction Irinotecan and Cisplatin in Patients With C-Kit Positive Extensive SCLC	Completed	Phase 2	United States	2005-09-07
194	Treatment of Philadelphia-Positive Acute Lymphocytic Leukemia (Ph+ ALL) in the Elderly With Imatinib Mesylate (STI571) and Chemotherapy.	Active, not recruiting	Phase 2	France	2005-09-06
195	AFR10 - Combination Therapy of Imatinib Mesylate (IM) + Alpha-2A Interferon for Chronic Phase CML Patients Resistant or Refractory to IM Used as Single Therapy for at Least One Year	Active, not recruiting	Phase 2	France	2005-09-05
196	A Study of Gleevec in Patients With Idiopathic Myelofibrosis or Chronic Myelomonocytic Leukemia (CMML)	Completed	Phase 2	United States	2005-08-25
197	Phase2 Study of Glivec (imatinib mesylate, formerly known as STI571) in Patients with Relapsed or Refractory Sarcomas with c-kit or PDGFR Expression	Terminated	Phase 2	Japan;Japan	2005-08-22

198	Gleevec Idiopathic Pulmonary Fibrosis (IPF) Study	Completed	Phase 2/Phase 3		2005-08-17
199	Glivec plus chemotherapy in blast-phase CML and Ph+ ALL		Phase 2	Australia	2005-08-04
200	A randomized open-label study of 400 mg versus 800 mg of Gleevec/Glivec (imatinib mesylate) in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase (CML-CP) using molecular endpoints Estudio abierto, aleatorizado de		N/A	Czech Republic;Spain;Italy	2005-07-27
201	Efficacy of 400 Mg Versus 800 Mg Imatinib in Chronic Myeloid Leukemia in Chronic Phase Patients - TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity)	Terminated	Phase 3	United States;Argentina;Australia;Brazil;Canada;Italy;United States;Argentina;Australia;Brazil;Canada	2005-07-27
202	Imatinib in Dermatofibrosarcoma Protuberans (DFSP)	Completed	Phase 1/Phase 2	Germany	2005-07-20
203	Study Comparing 12 Months Versus 36 Months of Imatinib in the Treatment of Gastrointestinal Stromal Tumor (GIST)	Completed	Phase 3	Sweden	2005-06-30
204	PTK787/ZK222584 in the Treatment of Metastatic Gastrointestinal Stromal Tumors Resistant to Imatinib	Completed	Phase 2	Finland	2005-06-30
205	Trial Evaluating Gleevec in Patients With Anaplastic Thyroid Carcinoma	Terminated	Phase 2	United States	2005-06-23
206	PHASE II STUDY OF IMATINIB MESYLATE IN CHORDOMA	Completed	phase 2	Italy	2005-06-16
207	Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor	Completed	Phase 2	Austria;Germany;Austria;Germany	2005-06-02
208	A TREATMENT PROTOCOL FOR PATIENTS WITH GASTROINTESTINAL STROMAL TUMOR WHO ARE INELIGIBLE FOR PARTICIPATION IN OTHER SU011248 PROTOCOLS AND ARE REFRACTORY TO OR INTOLERANT OF IMATINIB MESYLATE	Ongoing	phase 3	Finland;Hungary;United Kingdom;Denmark;Spain;Italy;Greece;Sweden	2005-02-22

209	Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia	Completed	Phase 2	United States;Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Denmark;Estonia;Finland;France	2005-02-15
210	An open label study of AMG 706 in subjects with advanced gastrointestinal stromal tumors (GISTs) who developed progressive disease or relapsed while on Imatinib Mesylate.	Completed	phase 2	Germany;Italy;United Kingdom	2005-02-10
211	Dasatinib (BMS-354825) in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate	Completed	Phase 2	United States;Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Korea, Re	2005-01-13
212	Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib	Completed	Phase 2	United States;Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Ireland;Israel;Italy;K	2005-01-12
213	Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia	Completed	Phase 2	United States;Argentina;Australia;Austria;Belgium;Brazil;Canada;Denmark;Finland;France;Germany;Israe	2005-01-12
214	Study of Dasatinib (BMS-354825) in Patients With Accelerated Phase Chronic Myeloid Leukemia	Completed	Phase 2	United States;Argentina;Australia;Belgium;Brazil;Canada;Denmark;Finland;France;Germany;Israel;Italy;	2005-01-12
215	17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate	Completed	Phase 1	United States	2005-01-07
216	Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia	Terminated	Phase 1	United States;China;Hong Kong;Singapore	2005-01-07
	A Phase II Study to Determine the Activity of BMS-354825 in				

217	Subjects with Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Have Disease that is Resistant to High Dose Imatinib Mesylate (Gleevec) or Who are Intolerant of Imati	Completed	phase 2	Finland;Spain;Ireland ;Denmark;Austria;Germany;Italy;United Kingdom;Sweden	2004-12-21
218	A Randomized Multi-center Open Label Study of BMS-354825 vs. Imatinib Mesylate (Gleevec) 800 mg/d in Subjects with Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Have Disease That is Resistant to Imatinib at a Dose at 400 -	Completed	phase 2	Estonia;Hungary;Finland;Spain;Ireland;Denmark;Austria;Germany;United Kingdom;Sweden	2004-12-21
219	Glivec (imatinib mesylate) in combination with hydroxyurea or hydroxyurea alone as an oral therapy in temozolomide resistant progressive glioblastoma patients			Denmark	2004-11-23
220	A Phase II Study of BMS-354825 in Subjects with Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate Revised Protocol 01: Incorporates Amendment 03 and Administrative Letter dated 25-February-2005. Amendment 01	Completed	phase 2	Finland;United Kingdom;Denmark;Italy;Sweden	2004-11-08
221	A Phase II Study of BMS-354825 in Subjects with Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib Mesylate Revised Protocol 01: Incorporates Amendment	Completed	phase 2	Finland;Germany;United Kingdom;Denmark;Italy;Sweden	2004-11-08
222	A Phase II Study of BMS-354825 in Subjects with Accelerated Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate Revised Protocol 01: Incorporates Amendment 03 and Administrative Letter dated 01-March-2005. Amendment 01 coun	Completed	phase 2	Finland;Germany;United Kingdom;Denmark;Italy;Sweden	2004-11-08

223	Intermediate and high risk localized, completely resected, gastrointestinal stromal tumors (GIST) expressing KIT receptor: a controlled randomized trial on adjuvant Imatinib mesylate (Glivec) versus no further therapy after complete surgery	Ongoing	phase 3	Spain;Denmark;Germany;Italy;United Kingdom	2004-10-14
224	A Treatment Protocol for Patients With Gastrointestinal Stromal Tumor (GIST) Who May Derive Benefit From Treatment With SU011248	Approved for marketing		United States;Argentina;Australia;Austria;Belgium;Canada;Chile;Colombia;Czech Republic;Denmark;Finland	2004-10-08
225	Everolimus and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission After Previous Imatinib Mesylate	Completed	Phase 1/Phase 2	United States	2004-10-06
226	THERAPEUTIC AND BIOLOGICAL EFFECTS OF IMATINIB MESYLATE (STI571) IN PRIMARY HYPERESINOPHILIC SYNDROME (HES), CHRONIC EOSINOPHILIC LEUKEMIA (CEL) AND CHRONIC IDIOPHATIC HYPEREOSINOPHILIA (CIH): A STUDY FROM THE NORTHERN ITALY LEUKEMIA GROUP (NILG)	Completed	phase 2	Italy	2004-09-17
227	Imatinib Mesylate in Treating Patients With HIV-Related Kaposi's Sarcoma	Completed	Phase 2	United States	2004-09-07
228	Oblimersen and Imatinib Mesylate in Treating Patients With Advanced Gastrointestinal Stromal Tumors That Cannot Be Removed By Surgery	Terminated	Phase 2	United States	2004-09-07
229	Study of AMG 706 in Subjects With Advanced Gastrointestinal Stromal Tumors (GISTs)	Completed	Phase 2	United States;Belgium;Canada;France;Germany;Italy;United Kingdom	2004-08-18
230	S0338, Imatinib Mesylate and Capecitabine in Treating Women With Progressive Stage IV Breast Cancer	Completed	Phase 2	United States	2004-07-08



231	A pilot study of continuous imatinib mesylate (IM) versus pulsed imatinib with or without lenograstim (recombinant human granulocyte colony stimulating factor [rHu-GCSF]) in chronic myeloid leukaemia (CML) patients who have achieved a complete cytogenetic			United Kingdom	2004-07-05
232	Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans or Giant Cell Fibroblastoma	Completed	Phase 2	Belgium;France;Netherlands;United Kingdom;Belgium;France;Netherlands;United Kingdom	2004-06-10
233	Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma Protuberans	Completed	Phase 2	United States	2004-06-10
234	Trastuzumab and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic HER2/Neu-Expressing Cancer	Completed	Phase 1	United States	2004-06-10
235	Docetaxel and Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases That Progressed on the Docetaxel and Placebo Group of MDA-ID-030008	Completed	Phase 2	United States	2004-06-10
236	Docetaxel With or Without Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases	Completed	Phase 2	United States	2004-04-07
237	Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia	Completed	Phase 1/Phase 2	United States	2004-04-07
238	Docetaxel and Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Breast Cancer	Completed	Phase 1	United States	2004-04-07
239	Imatinib Mesylate in Treating Patients With Recurrent or	Completed	Phase 2	United States	2004-01-09

	Persistent Uterine Cancer				
240	A Study To Assess The Safety And Efficacy Of SU11248 In Patients With Gastrointestinal Stromal Tumor(GIST)	Completed	Phase 3	United States;Australia;Belgium;Canada;France;Italy;Netherlands;Singapore;Spain;Switzerland;United K	2004-01-06
241	Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers	Completed	Phase 1/Phase 2	United States	2003-12-10
242	Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia	Active, not recruiting	Phase 2	United States;Canada;United States;Canada	2003-10-03
243	S0331: Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer	Completed	Phase 2	United States	2003-09-10
244	Imatinib Mesylate and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Myelogenous Leukemia	Completed	Phase 1	United States	2003-08-06
245	Flavopiridol and Imatinib Mesylate in Treating Patients With Hematologic Cancer	Completed	Phase 1	United States	2003-07-08
246	BMS-354825 in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Is Resistant to Imatinib Mesylate	Completed	Phase 1	United States	2003-07-08
247	Imatinib Mesylate in Treating Patients With Recurrent Ewing's Family of Tumors or Desmoplastic Small Round-Cell Tumor	Completed	Phase 2	United States	2003-06-05
248	Imatinib Mesylate With or Without Interferon Alfa or Cytarabine Compared With Interferon Alfa Followed by Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia	Recruiting	Phase 3	Germany;Switzerland;Germany;Switzerland	2003-03-06
	Imatinib Mesylate and				

249	Decitabine in Treating Patients With Chronic Myelogenous Leukemia	Completed	Phase 2	United States	2003-02-05
250	Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia	Completed	Phase 1/Phase 2	United States	2003-01-27
251	Imatinib Mesylate in Treating Patients With Recurrent Small Cell Lung Cancer	Completed	Phase 2	United States	2003-01-24
252	Combination Chemotherapy and Imatinib Mesylate in Treating Patients With Extensive-Stage Small Cell Lung Cancer	Completed	Phase 1	Canada	2003-01-24
253	High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML)	Completed	Phase 3	United States	2002-12-12
254	Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor	Active, not recruiting	Phase 1/Phase 2	United States	2002-11-12
255	Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia	Completed	Phase 2	United States	2002-11-12
256	Combination Chemotherapy and Imatinib Mesylate in Treating Children With Relapsed Acute Lymphoblastic Leukemia	Completed		United States;Australia;Canada;Netherlands;New Zealand;Puerto Rico;Switzerland	2002-11-12
257	Study of Lonafarnib and Gleevec in Chronic Myelogenous Leukemia	Completed	Phase 1	United States	2002-10-08
258	Imatinib Mesylate in Treating Patients With Salivary Gland Cancer	Completed	Phase 2	United States;Canada;United States;Canada	2002-09-06
259	Imatinib Mesylate in Treating Patients With Metastatic Breast Cancer	Completed	Phase 2	United States	2002-09-06
260	Imatinib Mesylate in Treating Patients With Recurrent Meningioma	Completed	Phase 2	United States	2002-09-06
261	Imatinib Mesylate and Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer	Completed	Phase 1	United States	2002-09-06

262	Interferon Alfa and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia	Completed	Phase 2	United States	2002-09-06
263	Imatinib Mesylate to Treat Myeloproliferative Hypereosinophilic Syndrome	Recruiting	Phase 2	United States	2002-08-24
264	Imatinib Mesylate in Treating Patients With Progressive, Refractory, or Recurrent Stage II or Stage III Testicular or Ovarian Cancer	Terminated	Phase 2	United States;Canada;Puerto Rico	2002-08-05
265	Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Chronic Phase Who Are Refractory to Imatinib Mesylate (Gleevec)	Completed	Phase 2	United States;Canada;United States;Canada	2002-07-19
266	Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec)	Completed	Phase 2	United States;Canada;United States;Canada	2002-07-19
267	Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Accelerated Phase Who Are Refractory to Imatinib Mesylate (Gleevec)	Completed	Phase 2	United States;Canada;United States;Canada	2002-07-19
268	Imatinib Mesylate in Treating Patients With Primary Gastrointestinal Stromal Tumor That Has Been Completely Removed By Surgery	Completed	Phase 3	United States;Canada	2002-07-08
269	Imatinib Mesylate in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer	Completed	Phase 2	United States	2002-07-08
270	Imatinib Mesylate in Treating Patients With Stage IV Colorectal Cancer	Completed	Phase 2	United States	2002-07-08
271	Zarnestra and Gleevec in Chronic Phase Chronic Myelogenous Leukemia	Completed	Phase 1	United States	2002-06-19
272	Chemotherapy, Imatinib Mesylate, and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia	Completed	Phase 2	United States	2002-06-06

273	Imatinib Mesylate in Treating Patients With Gliomas	Completed	Phase 2	Austria;Belgium;France;Italy;Netherlands;Switzerland;United Kingdom;Austria;Belgium;France;Italy;Netherlands	2002-06-06
274	Imatinib Mesylate in Treating Patients With Myelofibrosis	Completed	Phase 2	United States	2002-06-06
275	Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential Tumor	Completed	Phase 2	United States	2002-06-06
276	Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate	Completed		United States	2002-06-04
277	Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia	Completed	Phase 2	United States	2002-06-03
278	Phase I Trial of Fixed Dose STI571 (Imatinib Mesylate) With Escalating Doses of Docetaxel in Patients With Metastatic Androgen-Independent Prostate Cancer	Completed	Phase 1	United States	2002-05-29
279	Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatin	Active, not recruiting	Phase 2	United States	2002-05-13
280	Imatinib Mesylate in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer	Completed	Phase 2	United States	2002-05-13
281	Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma	Completed	Phase 2	United States	2002-03-08
				United	

282	Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood	Completed	Phase 2	States;Australia;Canada;Netherlands;New Zealand;Puerto Rico;Switzerland	2002-02-14
283	Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia	Completed	Phase 2	United States;Australia;Canada;Puerto Rico;Switzerland;Netherlands;New Zealand	2002-02-14
284	Imatinib Mesylate and Cytarabine in Treating Patients With Newly Diagnosed Chronic Myeloid Leukemia	Active, not recruiting	Phase 1/Phase 2	Belgium;Netherlands;Belgium;Netherlands	2002-01-04
285	Imatinib Mesylate in Treating Patients With Metastatic Melanoma	Completed	Phase 2	United States	2001-12-07
286	Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor	Completed	Phase 2	United States;Australia;Peru;Puerto Rico;South Africa	2001-12-07
287	Imatinib Mesylate in Treating Patients With Advanced Cancer and Kidney Failure	Completed	Phase 1	United States	2001-11-09
288	Imatinib Mesylate in Treating Patients With Gastrointestinal Stromal Tumor That Has Been Completely Removed During Surgery	Completed	Phase 2	United States	2001-10-11
289	Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction	Completed	Phase 1	United States	2001-10-11
290	Imatinib Mesylate Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia	Terminated	Phase 2	United States	2001-08-10
291	Imatinib Mesylate With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed or Recurrent Glioma	Terminated	Phase 1/Phase 2	United States	2001-07-11
292	Imatinib Mesylate and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia	Terminated	Phase 2	United States	2001-05-06
	Imatinib Mesylate in Treating		Phase		

293	Patients With Recurrent Malignant Glioma or Meningioma	Completed	1/Phase 2	United States	2001-02-02
294	Imatinib Mesylate With or Without Hydroxychloroquine in Treating Patients With Chronic Myeloid Leukemia	Recruiting	Phase 2		2010-10-21
295	Imatinib Mesylate With or Without Surgery in Treating Patients With Metastatic Gastrointestinal Stromal Tumor That is Responding to Imatinib Mesylate	Terminated	Phase 3		2009-08-08
296	Efficacy of Imatinib Mesylate in Hypereosinophilic Syndromes	Completed	Phase 2		2008-11-06
297	Nilotinib and Imatinib Mesylate in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia	Completed	Phase 2		2008-10-08
298	Treatment of Patients With Everolimus and Imatinib Mesylate Who Have Progressive Gastro Intestinal Stromal Tumors (GIST) and Are Resistant to Imatinib Mesylate	Completed	Phase 4		2007-07-31
299	BMS-354825 or Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Previous Imatinib Mesylate	Active, not recruiting	Phase 2		2005-06-02
300	Imatinib Mesylate or Observation Only in Treating Patients Who Have Undergone Surgery for Localized Gastrointestinal Stromal Tumor	Active, not recruiting	Phase 3		2005-02-07
301	Pioglitazone and Imatinib for CML Patients	Completed	Phase 2	France	2016-08-19
302	BA/BE study of Imatinib Mesylate 400 mg Tablets	Not Recruiting		India	2016-08-05
303	A Prospective Randomized Phase II Study Evaluating the Monitoring of Imatinib Mesylate Plasmatic Through Level in Patients Newly Diagnosed With CP-CML	Active, not recruiting	Phase 2	France	2016/9/7
	Bioequivalence Study Of Imatinib Mesylate Tablets 400				

304	mg Of Cadila Healthcare Ltd., India And Gleevec?? (Imatinib Mesylate) Tablets 400 mg Of Novartis Pharmaceuticals Corporation, USA In Patients With Gastrointestinal Stromal Tumors Or Chronic Myeloid	Not Recruiting	N/A	India	2016- 10-24
305	Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia	Not recruiting	Phase 3	United States	2016- 12-28

### 美国专利状态(15条)

序号	申请号	专利号	专利到期日	化合物专利	产品专利	专利用途码	专利撤销标识
1	021335	6894051	2019-05-23	Y	Y	U-649	
2	021335	6894051*PED	2019-11-23				
3	021335	6958335	2021-12-19			U-791	
4	021335	6958335*PED	2022-06-19				
5	021335	RE43932	2018-07-16	Y	Y		
6	021335	RE43932*PED	2019-01-16				
7	021588	6894051	2019-05-23	Y	Y	U-649	
8	021588	6894051*PED	2019-11-23				
9	021588	6958335	2021-12-19			U-1883	
10	021588	6958335	2021-12-19			U-791	
11	021588	6958335*PED	2022-06-19				
12	021588	7544799	2018-07-16	Y	Y		Y
13	021588	7544799*PED	2019-01-16				
14	021588	RE43932	2018-07-16	Y	Y		
15	021588	RE43932*PED	2019-01-16				

### 更多详细信息

[FDA物质编码库](#)
[药物合成数据库](#)
[药品中标数据库](#)
[TOP200数据库](#)



